With an anticipated price point of less than Rs 150 per dose, this will be the first time an Indian company will be able to adopt the highly productive C1-cell protein production platform.
Akston Biosciences Receives Regulatory Approval for Phase II Clinical Trial for Shelf-Stable COVID-19 Vaccine Booster - read this article along with other careers information, tips and advice on BioSpace